


TB Vaccines:

What advocates should watch for in 2024


GFAN | February 7, 2024

Mike Frick

Once available, new TB vaccines will be one of many ways to prevent TB



These are not discrete choices (A *not* B) but instead interventions that work better when used together (A+B). **No silver bullets, but lots of powerful tools.**



The Pipeline

The TB Vaccine Pipeline by the Numbers

17 candidate vaccines in the pipeline

6 candidates in phase III trials

5 trials that include PLHIV ongoing or expected to start soon

28 countries with a registered TB vaccine trial on **5** continents

>80,000 participants to take part in ongoing and planned phase III trials

\$143 million spent on TB vaccine R&D in 2022 (versus \$1.25 billion needed each year)

M72/AS01E

Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis Vaccine Candidate That Could Be the First in 100 Years If Proven Effective

“To support the M72 Phase III clinical trial, which will cost an estimated US\$550 million, Wellcome is providing up to US\$150 million and the Gates Foundation will fund the remainder, about US\$400 million.”

MTBVAC

December 18, 2023

IAVI and Zenda announce funding for efficacy trial of promising TB vaccine candidate in Africa

“The Gates Foundation has awarded IAVI US\$55 million to conduct a Phase IIb trial assessing the safety and efficacy of the TB vaccine candidate MTBVAC ... This funding has been made possible in part through a grant provided by Open Philanthropy. This trial is also supported by additional funding provided by the German Federal Ministry of Education and Research through KfW Development Bank.”

Promising science is no guarantee of success

[Home](#) / [News](#) / [2023](#) / [Early results on the A 055 POR trial](#)

Development of the Candidate Tuberculosis Vaccine H56:IC31 Ended Based on Early Data from the Prevention of Recurrence (POR) TB Consortium

Vaccine Well Tolerated and Demonstrated Immunogenicity But Did Not Provide Protection Against TB Recurrence;

Participants Being Informed; Further Analysis Continues

Updated 19 December 2023



“While the results are disheartening, it underscores the need for TB vaccine research and generating data to help move science forward. Ultimately there are no ‘bad’ results, because investigators collected data that we learn from. Knowing what doesn’t work may help us to discover what does.”

– Ani Herna Sari, co-chair of the Global TB Community Advisory Board (Global TB CAB).

R&D+D

After research and development comes delivery
Who leads?



PEPFAR

U.S. President's Emergency Plan for AIDS Relief




**THE
GLOBAL
FUND**



Stop TB Partnership
**GLOBAL DRUG
FACILITY**



Promising science is no guarantee of accessibility, availability, and affordability



How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits

by Anna Maria Barry-Jester

Oct. 4, 2023, 5 a.m. EDT



Thanks! (+ links)

- **TAG TB vaccine pipeline report:**
<https://www.treatmentactiongroup.org/resources/pipeline-report/2023-pipeline-report/>
- **M72/AS01E phase III trial press release:**
<https://www.gatesfoundation.org/ideas/media-center/press-releases/2023/06/funding-commitment-m72-tb-vaccine-candidate>
- **MTBVAC efficacy trial press release:** <https://www.iavi.org/press-release/iavi-and-zendal-announce-funding-for-efficacy-trial-of-promising-tb-vaccine-candidate-in-africa/>
- **H56:IC31 discontinuation and early results:**
<https://www.porconsortium.org/news/2023/early-results-on-the-a-055-por-trial>
- **TAG and Global TB CAB statement on H56:IC31:**
<https://www.treatmentactiongroup.org/statement/statement-from-tag-global-tb-cab-on-h56ic31-phase-iib-trial-results/>
- **ProPublica article on M72 access concerns:** <https://www.propublica.org/article/how-big-pharma-company-stalled-tuberculosis-vaccine-to-pursue-bigger-profits>